Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-5 of 5 for your search:
Drug:
dalteparin
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Randomized Study of Dalteparin for Venous Thromboembolism Prophylaxis in Patients With Lung Cancer
Phase:
Phase III
Type:
Supportive care
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
WCTU-FRAGMATIC
, Velindre-FRAGMATIC, WCTU-02, EU-20753, WCTU-02, PFIZER-WCTU-02, WCTU-FRAGMATIC, EUDRACT-2005-002438-37, ISRCTN80812769, NCT00519805
2.
Phase III Randomized Study of Gemcitabine Hydrochloride With or Without Capecitabine With or Without Preventive Anticoagulation Comprising Dalteparin in Patients With Metastatic Pancreatic Cancer
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Supportive care, Treatment
Status:
Active
Age:
18 to 80
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
GERCOR-PAM07-D07-2
, GERCOR-PAM07-D07-2, EUDRACT 2007-002115-59, EU-20837, PFIZER-GERCOR-PAM07-D07-2, NCT00662688
3.
A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients
Phase:
Phase III
Type:
Supportive care
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
NHLBI, Other, Pharmaceutical / Industry
Protocol IDs:
25387
, 1 R01 HL95109-01, NCT00876915
4.
Phase II Randomized Study of Gemcitabine Hydrochloride With Versus Without Dalteparin in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Supportive care, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
PRH-HCTU-FRAGEM
, PRH-HCTU-FRAGEM-V-12.1, CTA-MF8000/13558, EU-20721, LILLY-PRH-HCTU-FRAGEM, FRAGEM, ISRCTN76464767, NCT00462852
5.
DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study
Phase:
No phase specified
Type:
Supportive care
Status:
Active
Age:
30 and over
Sponsor:
Other
Protocol IDs:
2004-0743
, NCT00525057
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute